Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEPENDAX: axitinib + metronomic etoposide in relapsed/refractory pediatric medulloblastoma and ependymoma
2023-509585-38-00Phase 2Authorised
- Sponsor
- Assistance Publique-Hôpitaux de Marseille
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of axitinib and etoposide in medulloblastoma and ependymoma, sponsored by Assistance Publique-Hôpitaux de Marseille. Primary endpoints: Dose-limiting toxicity (DLT) in first 28-day cycle and Progression-free survival (PFS). Planned start Oct 2024; status: authorised.
02
Drugs
axitinibetoposide
03
Conditions
medulloblastomaependymoma
Beyond the preview
Go deeper on 2023-509585-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509585-38-00.